Joseph Massaro, DO
Interventional Cardiology · Lakeland, FLNPI 1316910466
Payments from drug & device makers
Across 43 payments — averaging $95.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocardia, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Medtronic$294
- Boston Scientific$214
- Edwards Lifesciences$174
- Abbott$145
- plus $508 from 13 others
Across 1 payment — averaging $875.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$875
What the payments were for
- Consulting fees$2,75067%
- Food & beverage$1,31432%
- Education$221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocardia, Inc. | 1 | $1,700 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,050 |
| Medtronic | 11 | $294 |
| Boston Scientific | 2 | $214 |
| Edwards Lifesciences | 2 | $174 |
| Abbott | 1 | $145 |
| Cardiovascular Systems Inc. | 2 | $89 |
| Merck | 4 | $68 |
| Novartis | 2 | $58 |
| Boehringer Ingelheim | 2 | $57 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $46 |
| Abiomed | 1 | $34 |
| Pfizer | 2 | $32 |
| Amgen | 2 | $28 |
| AstraZeneca | 2 | $25 |
| Shockwave Medical, Inc | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,085 in reported general payments places this provider in the 25th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 196 | $206,158 |
| EntrestoSacubitril/Valsartan | 63 | $63,884 |
| XareltoRivaroxaban | 30 | $36,874 |
| Repatha SyringeEvolocumab | 12 | $6,578 |
| VascepaIcosapent Ethyl | 15 | $4,381 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $3,274 |
| Ranolazine ErRanolazine | 22 | $2,659 |
| Rosuvastatin Calcium | 88 | $2,068 |
| ClopidogrelClopidogrel Bisulfate | 184 | $2,047 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 106 | $1,657 |
| Carvedilol | 167 | $1,436 |
| Bumetanide | 32 | $1,357 |
| Metoprolol Succinate | 91 | $1,328 |
| Nitroglycerin | 107 | $1,289 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 37 | $1,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $206,158196 claims |
| NovartisEntresto | $58 | $63,88463 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Lakeland
- Douglas EbersoleLakeland$373K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.